4D Molecular Therapeutics, Inc. (FDMT) has a negative trailing P/E of -4.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -24.68%.
Criteria proven by this page:
Overall SharesGrow Score: 58/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -53.5 | 0.00 | -30.67 | 103.77 | - |
| 2018 | -53.1 | 0.00 | -18.38 | 35.88 | - |
| 2019 | -21.8 | -0.13 | -14.70 | 153.59 | - |
| 2020 | -19.5 | -3.25 | 4.31 | 81.25 | - |
| 2021 | -8.5 | -0.53 | 1.91 | 33.73 | - |
| 2022 | -6.7 | -0.25 | 3.11 | 229.63 | - |
| 2023 | -7.9 | 0.45 | 2.58 | 38.26 | - |
| 2024 | -1.9 | -0.12 | 0.59 | 8,120.72 | - |
| 2025 | -3.1 | 0.17 | 0.86 | 5.10 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-0.76 | $5.79M | $-11.22M | -193.8% |
| 2018 | $-0.76 | $14.13M | $-9.55M | -67.6% |
| 2019 | $-2.00 | $6.99M | $-52.94M | -757.8% |
| 2020 | $-2.12 | $13.61M | $-56.54M | -415.4% |
| 2021 | $-2.46 | $18.04M | $-68.3M | -378.6% |
| 2022 | $-3.12 | $3.13M | $-101.08M | -3230.3% |
| 2023 | $-2.58 | $20.72M | $-100.84M | -486.6% |
| 2024 | $-2.98 | $37K | $-160.87M | -434778.4% |
| 2025 | $-2.42 | $85.21M | $-140.11M | -164.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.82 | $-4.55 – $-2.87 | $7.78M | $51.66K – $15.5M | 6 |
| 2027 | $-3.80 | $-4.67 – $-2.98 | $12.71M | $79.71K – $25.35M | 5 |
| 2028 | $-3.87 | $-6.48 – $-2.77 | $39.31M | $253.59K – $78.36M | 4 |
| 2029 | $-3.59 | $-8.23 – $1.05 | $117.83M | $760.19K – $234.9M | 2 |
| 2030 | $-2.43 | $-5.57 – $0.71 | $257.36M | $1.66M – $513.06M | 2 |
